| Literature DB >> 34597754 |
Lu Zhang1, Xiao-Jing-Nan Ma2, Yuan-Yuan Fei3, Heng-Tong Han2, Jun Xu2, Lu Cheng4, Xun Li5.
Abstract
The liver has the ability to repair itself after injury; however, a variety of pathological changes in the liver can affect its ability to regenerate, and this could lead to liver failure. Mesenchymal stem cells (MSCs) are considered a good source of cells for regenerative medicine, as they regulate liver regeneration through different mechanisms, and their efficacy has been demonstrated by many animal experiments and clinical studies. Induced pluripotent stem cells, another good source of MSCs, have also made great progress in the establishment of organoids, such as liver disease models, and in drug screening. Owing to the recent developments in MSCs and induced pluripotent stem cells, combined with emerging technologies including graphene, nano-biomaterials, and gene editing, precision medicine and individualized clinical treatment may be realized in the near future.Entities:
Keywords: Gene editing; Induced pluripotent stem cells; Liver regeneration; Mesenchymal stem cells; Organoids; Regenerative medicine
Mesh:
Year: 2021 PMID: 34597754 DOI: 10.1016/j.pharmthera.2021.108004
Source DB: PubMed Journal: Pharmacol Ther ISSN: 0163-7258 Impact factor: 12.310